Clinical Trials Browser

OTHER × Melanoma × lorukafusp alfa × Clear all

NCT03958383 2025-04-18

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

Phase 1/2 Active not recruiting

Melanoma

NCT00590824 2019-11-21

Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma

Phase 2 Completed

23 enrolled 22 charts

Melanoma

NCT00109863 2019-11-19

Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma

Phase 2 Completed

Melanoma